Lexaria Bioscience Regains Nasdaq Bid-Price Compliance

What Happened Lexaria Bioscience Corp. (ticker: LEXX) announced in an 8-K filed August 17, 2026 that it received a letter from the Hearings Advisor of The Nasdaq Stock Market. Nasdaq's Listings Qualifications Staff confirmed the company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the minimum $1 bid-price requirement). As a result, the previously requested hearing was cancelled and Lexaria's common stock will continue to be listed and traded on The Nasdaq Capital Market.

Key Details

• Filing: Form 8-K filed August 17, 2026 (Item 8.01: Other Events).
• Rule referenced: Nasdaq Listing Rule 5550(a)(2) — the $1 minimum bid-price requirement.
• Outcome: Nasdaq confirmed compliance; the previously requested hearing was cancelled.
• Impact: Lexaria’s Common Stock will continue to be listed and traded on The Nasdaq Capital Market.

Why It Matters This confirms Lexaria avoided a Nasdaq hearing tied to a bid-price deficiency and maintains its Nasdaq listing and trading status, preserving market access and liquidity for shareholders. The filing contains no additional operational or financial updates.